CH:B4V Stock Latest News
Company AnnouncementsArcticZymes to Present Q3 and Nine-Month 2026 Results in Live Webcast3d ago
Company AnnouncementsArcticZymes Targets RNA Therapeutics With Cost-Cutting Enzyme Launch5d ago
Company AnnouncementsArcticZymes Showcases Strategy at Swiss Nordic Bio 20261M ago
Company AnnouncementsArcticZymes CEO to Present at Pareto Healthcare Conference in Stockholm2M ago
Company AnnouncementsArcticZymes Converts Double-Digit Growth Into Earnings As Enzyme Business Accelerates2M ago
Pre-EarningsB4V Earnings this Week: How Will it Perform?2M ago
- Company AnnouncementsArcticZymes Shareholders Approve All Proposals at 2026 AGM5M ago
Company AnnouncementsArcticZymes Chair to Represent Over 11% of Shares at 2026 AGM5M ago- Company AnnouncementsArcticZymes Chair Secures Proxies Covering 5.1% of Shares Ahead of AGM5M ago
- Company AnnouncementsArcticZymes Delivers Strong Q1 2026 Growth and Returns to Profitability5M ago
Company AnnouncementsArcticZymes Sets May 28, 2026 Date for Hybrid Annual General Meeting5M ago
- Company AnnouncementsArcticZymes Wins Key Patent to Drive Expansion in RNA Therapeutics Manufacturing6M ago
Company AnnouncementsArcticZymes Deepens Bioprocessing R&D to Boost Viral Vector Manufacturing6M ago- Company AnnouncementsArcticZymes outlines scalable enzyme growth strategy at 2026 Capital Markets Day8M ago
Company AnnouncementsArcticZymes Schedules 2026 Capital Markets Day to Present Strategy and Growth Plans8M ago
Company AnnouncementsArcticZymes Cost Model Highlights Nuclease Strategy as Key Lever in Viral Vector Economics8M ago
Company AnnouncementsArcticZymes Sets Out Scalable Enzyme Growth Strategy at 2026 Capital Markets Day8M ago
